MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Rifaximin

CAS No. : 80621-81-4

MCE 國際站：Rifaximin

產(chǎn)品活性：Rifaximin是一種胃腸道選擇性的抗生素 (antibiotic)，與細(xì)菌 DNA 依賴性 RNA 聚合酶的 β 亞基結(jié)合，從而抑制細(xì)菌 RNA 的合成 (bacterial RNA synthesis)。與革蘭氏陰性菌（MIC：8-50 毫克/毫升）相比，Rifaximin對(duì)革蘭氏陽性菌株（MIC：0.03-5 毫克/毫升）的敏感性更高。

研究領(lǐng)域：Anti-infection  |  Cell Cycle/DNA Damage

作用靶點(diǎn)：Bacterial  |  Antibiotic  |  DNA/RNA Synthesis

In Vitro: Rifaximin has a good inhibitory activity against Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Shigella, Salmonella, Bacillus cereus, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Bacteroides bivius-disiens, Gardnerella vaginalis, Lactobacillus spp.,Mobiluncus spp.,Neisseria gonorrhoeae, Pseudomonas and Acinetobacter . Rifaximin rarely causes side effects.
Rifaximin (0.1, 1.0 and 10.0 µM) causes significant and concentration-dependent reduction of cell proliferation, cell migration and PCNA expression in the Caco-2 cells vs. untreated cells.
Rifaximin (0.1-10 μM) downregulates Akt/mTOR and p38MAPK/NF-κB pathways through a PXR-dependent mechanism.

In Vivo: Rifaximin administration (30 or 50 mg/kg/day) increases survival rates of colitic mice and reduces colitis severity by improvement of wasting syndrome, histologic scores, decrease in colon IL-2, IL-12, IFN-gamma and TNF-alpha (protein and mRNA) levels, and diminishes colon myeloperoxidase (MPO) activity.

相關(guān)產(chǎn)品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Macrocyclic Compound Library  |  Antibacterial Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Rapamycin  |  Cycloheximide  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  Oxaliplatin  |  Gemcitabine  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Cyclosporin A  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Ionomycin  |  Carboplatin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Bleomycin sulfate  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds